Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Interest & Investment Income (2024 - 2025)

Corvus Pharmaceuticals has reported Interest & Investment Income over the past 2 years, most recently at $603000.0 for Q4 2025.

  • Quarterly results put Interest & Investment Income at $603000.0 for Q4 2025, up 18.7% from a year ago — trailing twelve months through Dec 2025 was $2.5 million (up 37.34% YoY), and the annual figure for FY2025 was $2.5 million, up 37.34%.
  • Interest & Investment Income for Q4 2025 was $603000.0 at Corvus Pharmaceuticals, down from $738000.0 in the prior quarter.
  • Over the last five years, Interest & Investment Income for CRVS hit a ceiling of $738000.0 in Q3 2025 and a floor of $316000.0 in Q1 2024.